We explored the extent to which experimental validation of binding sites might alter our results by replacing connectivity data for the breast cancer subsets with ChlP-on-chip data for three TFs (Myc and E2F1), for which ChlP-on-chip data were available [29]. The gene discussed is E2F1; the disease is breast cancer.